Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for pimobendan in heart failure; human trials needed before any clinical consideration.
We investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50% mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals. After 340 days, survival was 0% for the untreated cardiomyopathic hamsters and 27% in the pimobendan-treated group. We conclude that pimobendan slows the progression of heart failure in cardiomyopathic hamsters.
No takes yet. Share an insight, caveat, or question.
Meel et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: